This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Aug 2015

Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-to-Treat Type of Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group, has announced positive results from the Phase II M13-982 study of venetoclax, an investigational medicine being developed in partnership with AbbVie. The study met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells (overall response rate, ORR) in a pre-defined proportion of people with previously treated (relapsed or refractory) chronic lymphocytic leukemia (CLL) harboring the 17p deletion. No unexpected safety signals were reported for venetoclax.

 

“Approximately 30–50% of people with relapsed or refractory chronic lymphocytic leukemia have the 17p deletion that makes their disease difficult to treat,” said Sandra Horning, chief medical officer and head of Global Product Development. “Venetoclax may help restore the natural process that allows these leukemic cells to self destruct, representing a potential new way of helping people with this form of CLL who typically have a poor prognosis and limited treatment options.”

 

Venetoclax was recently granted Breakthrough Therapy Designation (BTD) by the FDA for the treatment of previously treated CLL with the 17p deletion. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. People with this type of CLL typically have a median life expectancy of less than 3 years. This is the eighth BTD granted for a Genentech medicine, and the second one in hematology.

 

Data from the pivotal M13-982 study will be submitted for presentation at an upcoming medical meeting. AbbVie plans to submit these data to the FDA, European Medicines Agency (EMA) and other health authorities around the world for approval consideration.

Related News